{
  "id": 3682708,
  "title": "Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?",
  "url": "https://urgent.news/2026/08/25/fulcrum-fulc-is-allocating-95-of-the-combined-company-to-slate-and",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-25T18:28:24.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/fulcrum-fulc-allocating-95-combined-182824564.html"
  },
  "original_language": "en",
  "account": "Fulcrum Therapeutics, Inc. (NASDAQ:FULC) recently merged with Slate Medicines, transforming the publicly traded company into a migraine-focused biotechnology business. Slate Medicines contributed its drug assets, while new investors supplied $245 million. Legacy Fulcrum shareholders would own 5% of the combined company, while Slate Medicines would hold 55.9% and PIPE investors would own 39.1%, subject to adjustment. In exchange for the merger, Fulcrum Therapeutics, Inc. (NASDAQ:FULC) expects to distribute an estimated $270 million cash dividend, which equates to approximately $3.54 per share, based on 76.2 million shares outstanding as of July 23. This dividend, combined with a $0.41 stub, amounts to roughly $3.95 in gross illustrative value, surpassing Monday's closing price of $3.84 by 11 cents. The dividend's actual value will depend on several factors, including the closing net cash, share count, and other transaction adjustments.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}